Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business
Standard BioTools stockholders approved all proposals tied to its merger with Treeline Biosciences and the sale of its Mass Cytometry business to Element Biosystems, an acquisition vehicle formed by GMT Venture Partners. The company announced the vote results itself, so the approvals are on the record.
From the press release
BOSTON, Mass., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced that, at its Special Meeting of Stockholders held earlier today, stockholders approved all proposals related to the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”) and the sale of its Mass Cytometry business to Element Biosystems, LLC, an acquisition vehicle formed by GMT Venture Partners, LLC.
As published for republication. The full text is at GlobeNewswire.
Comments
Log in or create a free account to comment.
No comments yet.
The headline links to the original source; the summary is written by The Market Standard. Nothing here is financial advice.